• Contact us
  • Customer support
  • Login
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
XVIVO
  • Contact us
  • Customer support
  • Home
  • Technology
    • Introduction to Ex Vivo Lung Perfusion
    • The Ex Vivo Lung Perfusion Process
    • Clinical
    • Protocols
    • Starting your clinical EVLP program
    • Articles about EVLP
    • EVLP with Manual method
    • EVLP with XPS™
    • Training and workshops
    • Patents
  • Products
    • Our Products
    • XPS™
    • XPS Disposable Lung Kit™
    • STEEN Solution™
    • PERFADEX® Plus
    • XVIVO
      Organ Chamber™
    • XVIVO
      Lung Cannula Set™
    • Instruction for Use
  • Knowledge
    • NOVEL Lung Trial
    • Literature
    • Insights
  • Media
    • Videos
    • Webinars
    • Establishing a successful EVLP program
  • About us
    • About XVIVO
    • History
    • Our market
    • News
    • Career
    • Working at XVIVO
  • Corporate
    • Corporate
    • The share
      • Info
      • Ownership structure
      • Insiders (PDMRs)
    • Press releases
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
      • 2013
      • 2012
    • Financial calendar
    • Financial reports
    • Financial reports – ESEF
    • Prospectus and material offerings
      • Material offerings
      • Prospectus
    • Financial presentations
      • Capital Markets Day
      • Earnings calls
    • Corporate governance
      • Article of Association
      • General meetings
      • Board of Directors
      • Senior Management
      • Auditors
      • Board Committees
      • Board and Senior Management share holdings
      • Guidelines for remuneration
      • Nomination Committee
      • Corporate Governance Reports
    • Analyst Coverage
    • Code of Conduct
    • Environmental Policy
    • Code of Conduct for Suppliers
    • Privacy policy
    • Contact us
    • Subscribe
    • Thank you
    • Error
  • Corporate
  • The share
    • Info
    • Ownership structure
    • Insiders (PDMRs)
  • Press releases
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
  • Financial calendar
  • Financial reports
  • Financial reports – ESEF
  • Prospectus and material offerings
    • Material offerings
    • Prospectus
  • Financial presentations
    • Capital Markets Day
    • Earnings calls
  • Corporate governance
    • Article of Association
    • General meetings
    • Board of Directors
    • Senior Management
    • Auditors
    • Board Committees
    • Board and Senior Management share holdings
    • Guidelines for remuneration
    • Nomination Committee
    • Corporate Governance Reports
  • Analyst Coverage
  • Code of Conduct
  • Environmental Policy
  • Code of Conduct for Suppliers
  • Privacy policy
  • Contact us
  • Subscribe
  • Thank you
  • Error

Environmental Policy

XVIVO is a medical device company developing, manufacturing and distributing clinically optimized solutions and systems for use in connection with organ transplantation and priming heart and lung machines. The purpose of XVIVO’s products is to minimize injury of organs ex vivo, extend the preservation time, increase the organ availability and transplantation success rate. XVIVO is committed to provide safe and sustainable products and to be compliant with applicable laws, regulations, and standards where environment plays an important role. We are also committed to minimize the environmental impact of all operations and of our products.

Energy

XVIVO facilities consist 70% of office space and workshops. Warehouses make up the remaining 30 %. Energy consumption mainly comes from heating and lighting of these facilities. We have incorporated energy efficiency measures into our facilities and are promoting efficient energy use.

Chemicals

At XVIVO we evaluate new materials and chemicals in the product development process to ensure that we satisfy directives and regulations such as REACH – Registration, Evaluation, Authorization and Restriction of Chemicals and Restriction of Hazardous Substances (RoHS). In our facilities we are maintaining chemical registers and all new chemicals are assessed related to among other environmental impact. According to XVIVO’s policy, potential hazardous chemicals shall be replaced with less hazardous alternatives.

Production

XVIVO has outsourced all production of commercial products. All suppliers are required to meet the demands in the XVIVO Code of Conduct for Suppliers where it is stated that the supplier shall have procedures in place to secure compliance with the requirements of applicable environmental legislation and regulations. Also, the supplier shall have knowledge of the environmental impacts of its operations, and shall continuously strive to reduce impacts and improve environmental performance in a systematic way. Improvements should cover reduction of energy and water use, emissions and waste as well as the reduction and/or substitution of hazardous chemicals.

Suppliers have suitable environmental management systems and some are certified with ISO 14001.

Packaging

XVIVO strives to reduce unnecessary packaging. For transportation some of the packaging is reused. When possible we use recyclable packaging such as cardboard. XVIVO complies with requirements on packaging for Medical Device products. The source, history and traceability of all materials, especially recycled materials, shall be known and controlled to ensure that the sterile barrier system consistently meet the requirements. With current commercial technologies, it is unlikely that anything other than virgin manufacturing waste will be used in recycled materials, due to insufficient controls to allow the safe use of other recycled material in sterile barrier systems.

Transportation

XVIVO outsources transportation and uses transportation suppliers with strong environmental policy such as UPS and DSV. XVIVO are also striving to use more sea freight instead of air. We are continuously optimizing freight in order to reduce the number of transportations.

Internal air travel has decreased and has largely been replaced by permanent video meetings. When possible we travel with train instead of plane.

Waste

XVIVO follows the Waste Electrical and Electronic Equipment (WEEE) directive and takes a producer responsibility for our machines . The machines have life times of 10 years and almost all components are recyclable. Our operations have some impact on the environment and climate. Primarily through the use of our disposable products. Due to strict sterility requirements, a pre-requisite for guaranteeing patient safety, the reuse of disposable items is prohibited, which WHO also clearly stipulates. Recycling of our disposable products is not either an option due to biological contamination.

 

Document reviewed  and approved by CEO in May 2022.
This policy is reviewed on a regular basis to evaluate continued relevance and to monitor compliance.

 

About us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives.
Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine.
XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on three continents. The company is listed on Nasdaq.

Contact

Swedish Office
XVIVO Perfusion AB
Box 53015
SE-400 14 Göteborg
Sweden

Phone: +46 31 788 21 50
Fax: +46 31 788 21 69
info@xvivogroup.com

 

Report a violations or breach here: Whistleblower

  • Home
  • Technology
  • Products
  • Knowledge
  • Media
  • About us
  • Corporate

Copyright © 2023 XVIVO. All rights reserved.

Design mkmedia
To top

We use cookies to improve the user experience on XVIVO. Read more about Cookies

Approve